Google Launches $99 AI Health Coach; Whoop Counters with Real Doctors

At a glance:

• Google introduces a $99 screenless Fitbit Air and $9.99/month Gemini-powered AI health coach
• Whoop adds on-demand video consultations with licensed clinicians in response
• FDA’s 2026 regulatory changes enable both AI and human-led health tools without strict medical device classification

The Tracker: Google’s Minimalist Approach

Google’s Fitbit Air is a screenless fitness band priced at $99, designed to track heart rate, heart rate variability, SpO2, sleep stages, and activity continuously. With a one-week battery life, it lacks a display, forcing users to rely on the Google Health app for data access. This app, set to replace the Fitbit app on 19 May, emphasizes AI integration over hardware. The $99 device includes a three-month free trial of Google Health Premium ($9.99/month or $99/year), which features the AI Health Coach powered by Gemini. This coach generates workout plans, interprets sleep trends, and summarizes health records. Google’s strategy is clear: sell the AI layer, not the device. The Health app is wearable-agnostic, planning support for Apple Watch, Oura, and Garmin later this year. The Fitbit Air serves as an entry point, not a destination, positioning Google as the intelligence bridging all wearable data.

The device’s simplicity contrasts with its ambition. By removing the screen, Google forces users to engage with its AI ecosystem. This aligns with its broader goal of making health data actionable through algorithms rather than manual analysis. However, the lack of a display raises questions about user engagement. Without visual feedback, users may rely more heavily on the AI’s interpretations, potentially amplifying trust in its recommendations. Google’s approach also highlights a shift in the wearable market, where hardware is increasingly a conduit for software and AI services. The $99 price point undercuts competitors like Whoop, which charges $199–$359/year for subscriptions, making Google’s offering more accessible to price-sensitive consumers.

The Response: Whoop’s Human-Centric Counter

Whoop, a $10.1 billion company with 2.5 million members, responded to Google’s launch by adding on-demand video consultations with licensed clinicians. Available in the US this summer, these consultations begin with a review of the user’s biometric data from the Whoop band. If users have integrated blood work or medical history via HealthEx, an electronic health records integration Whoop is launching, that data is included. This approach emphasizes human judgment over algorithmic analysis. A clinician can ask follow-up questions, identify patterns requiring context, and carry professional accountability—something an AI coach cannot replicate. For example, while an AI might note a declining heart rate variability, a doctor could explain potential causes like stress or illness.

Whoop’s move reflects a philosophical stance: health data requires human expertise. The company, which raised $575 million in March 2026 at a $10.1 billion valuation, argues that AI should support, not replace, clinicians. This is evident in its pricing model: Whoop’s subscriptions cost $199–$359/year, with additional fees for consultations. In contrast, Google’s AI coach is priced at $9.99/month, undercutting Whoop’s base subscription. Whoop’s founder, Will Ahmed, even posted a message on X: “Don’t bother copying us, we will win,” a nod to Amazon’s failed Halo band. This defiance underscores Whoop’s confidence in its human-centric model, even as it faces a tech giant with vast resources.

The Economics: Price Wars and Market Dynamics

The pricing gap between Google and Whoop frames the competitive battle. Google’s $99 tracker plus $9.99/month AI coach costs less than Whoop’s cheapest plan. However, Whoop’s human consultations add a premium, potentially justifying its higher price for users seeking medical expertise. This creates a stark choice: Google’s AI-driven, low-cost model or Whoop’s human-led, higher-cost approach. Both strategies are coherent but untested at scale. Google’s success hinges on users trusting AI to interpret health data, while Whoop’s hinges on users valuing clinician insights.

The economic implications extend beyond pricing. Google’s model could democratize health guidance, making it accessible to a broader audience. Whoop’s approach, however, targets users willing to pay for personalized medical advice. The company’s financials are strong: $1.1 billion in annualized revenue in 2025, up 103% year-over-year, and cash-flow positive. This suggests Whoop has the resources to sustain its premium model. Meanwhile, Google’s focus on AI as a service could disrupt traditional health tech, where hardware sales have long dominated. The $99 price point for the Fitbit Air is a strategic move to attract users to its ecosystem, where the real value lies in the AI layer.

The Field: A Crowded AI Health Landscape

Google and Whoop are not alone in the AI health space. ChatGPT Health, launched in January 2026, connects Apple Health data to OpenAI models. Microsoft followed with Copilot Health, while Perplexity Health integrates electronic health records, wearable data, and lab results into an AI dashboard. Amazon also opened its Health AI to US customers, backed by One Medical and its pharmacy network. Every major AI platform now has a health product, turning wearable data into a battleground for AI models. The differentiation lies not in the data—heart rate, sleep stages, and SpO2 are measured by all devices—but in how the data is interpreted. Google’s Gemini-powered coach and Whoop’s clinician consultations represent two extremes: algorithmic analysis versus human expertise.

This competition is intensifying as AI capabilities improve. Corti’s Symphony AI, for instance, outperformed OpenAI and Anthropic models on medical coding benchmarks, showing that specialized health AI can surpass general-purpose models. For wearables, this means the AI interpreting data may matter more than the sensor collecting it. Google is betting on its AI to become the central intelligence for health decisions, while Whoop is routing around it to human clinicians. The result is a fragmented market where users must choose between convenience and expertise.

The Regulation: A New Era for Health Tech

The FDA’s 2026 regulatory changes have created a permissive environment for both Google and Whoop. The General Wellness Guidance allows low-risk wearables, like screenless fitness trackers, to sell wellness claims without premarket review. The Clinical Decision Support Guidance softened oversight for AI tools that assist in health decisions. This means Google’s AI coach can offer personalized guidance as wellness advice, avoiding medical device classification, while Whoop’s consultations operate under existing telemedicine frameworks. The key distinction is whether the AI makes clinical claims. An AI coach suggesting rest based on recovery scores is wellness advice; one diagnosing atrial fibrillation would cross into clinical territory.

The regulatory shift reflects a broader trend of treating health tech as a wellness tool rather than a medical one. This benefits both companies: Google can scale its AI coach without rigorous FDA approval, while Whoop can offer human consultations without classifying them as medical devices. However, the line between wellness and clinical advice remains blurred. As subscription costs rise and user expectations grow, the incentive to cross this line increases. Google’s $9.99/month coach and Whoop’s premium consultations are both positioned to navigate this regulatory gray area, but the long-term implications for user trust and legal accountability remain uncertain.

The Future: AI vs. Human Expertise

The clash between Google’s AI and Whoop’s clinicians is more than a product battle—it’s a debate about the role of technology in health. Google’s approach assumes that algorithms can interpret data as effectively as humans, potentially reducing costs and increasing accessibility. Whoop’s model, however, emphasizes the irreplaceable value of human judgment. This divide mirrors broader discussions in healthcare: can AI augment or replace professionals? Blossom Health’s model of AI copilots alongside psychiatrists offers a middle ground, but Whoop’s approach is more extreme, positioning humans as the final decision-makers.

The outcome will depend on user trust and regulatory evolution. If consumers prefer the convenience of AI, Google’s model could dominate. If they prioritize accuracy and accountability, Whoop’s human-led approach may prevail. The FDA’s current stance suggests both models are viable, but as health data becomes more integral to daily life, the debate will intensify. For now, the market is split, with each company betting on a different future: one where AI is the primary health advisor, and another where humans remain central.

Key Takeaways

• Google’s $99 AI health coach targets affordability and scalability, leveraging AI to interpret wearable data
• Whoop’s response with real doctors emphasizes human expertise and accountability
• FDA regulations in 2026 create a flexible framework for both AI and human-led health tools